GlaxoSmithKline Consumer Nigeria Plc announces the appointment of Mr. Oussama Abbas as a non-executive director on the board of the Company effective 29th July 2020, as Mr Basel Nizameddin, formerly a Non-Executive Director resigns from the Board of the Company with effect from 29th July 2020.
Mr. Nizameddin’s resignation was necessary to enable him to attend to other new assignments within the GSK Group.
The Board acknowledged the strong contributions of Mr. Nizameddin to the Board and wished him the best in his future endeavours.
APPOINTMENT OF NON-EXECUTIVE DIRECTOR
The Board of Directors of GlaxoSmithKline Consumer Nigeria Plc (GSK or the Company) wishes to announce the appointment of Mr. Oussama Abbas as a non- executive director on the board of the Company effective 29th July 2020.
Mr. Abbas currently Head of Supply Chain – Turkey, Middle East & Africa (MEA), Consumer Health Supply Chain (CHSC), is an accomplished industrial senior executive of GSK with proven abilities in international pharmaceutical, biotech and animal healthcare. He also has solid experience in leading manufacturing plants of commercial and clinical supply-chain operations.
He is deeply involved in corporate organizational changes with the understanding of the impact on other business functions.
Mr. Abbas has an International Executive MBA (High Distinction) from the Louvain School of Management – Belgium (1999); Doctorate Degree, Faculty of Pharmacy – University Claude Bernard (Lyon – France); Second Degree Master – Focus in Galenic (Formulation – Process – Production) – University Diploma of Pharmaceutical Management, Institut de la Pharmacie Industrielle de Lyon.
He joined GSK as Director, Secondary Manufacturability & Clinical Supply in May 2009 and has grown through the system to his current position as the Head of Supply Chain of MEA.
The Board is very confident that with his background, relevant experience and significant involvement in the Global Supply Chain network, Mr. Oussama Abbas would add significant value to the quality and diversity of the Board of GlaxoSmithKline Consumer Nigeria Plc.